• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Saudi Arabia·Healthcare·4005.SR
Share

National Medical Care Company Stocks

SAR 91.2Last Updated 26.10.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

SAR 1.09B

SAR 91.2
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

National Medical Care Company is dedicated to the comprehensive establishment, ownership, operation, and maintenance of healthcare facilities across the Kingdom of Saudi Arabia. Its substantial portfolio includes the 325-bed Riyadh Care Hospital, the 459-bed National Hospital, the Family Health Care Center, and the Care Company for Pharmaceutical and Medical Distribution. In addition to these institutional services, the company also provides home healthcare. Founded in 2003, it is headquartered in Riyadh, Saudi Arabia.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 4005.SR is 134 and suggests 47% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.10.2026 03:18

"The conditions for a rebound are ripe": Stocks rise for a second day ahead of big tech earnings reports

28.10.2026 03:13

Oracle is expanding its partnership with OpenAI and integrating Google chips into its infrastructure

28.10.2026 00:20

Memory stocks cool off in 2H26 amid AI spending doubts

27.10.2026 22:38

GM will move its listing to the Nasdaq. What does this mean for its stock?

27.10.2026 21:09

Boeing shares plunge as 737 Max ramp-up delays overshadow top-line growth in 3Q

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026